Preclinical investigation of PEGylated tumor necrosis factor α in dogs with spontaneous tumors: Phase I evaluation

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1498-1508

  Thamm, Douglas H ^a,b   Kurzman, Ilene D ^c,d   Clark, Mike A ^a   Ehrhart III, E J ^a,b   Kraft, Susan L ^a,b   Gustafson, Daniel L ^a,b   Vail, David M ^c,d  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; ONDANSETRON; PEGYLATED TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CLOTTING DISORDER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CONTRAST ENHANCEMENT; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FEVER; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NECROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TOXICITY TESTING; TUMOR BIOPSY; TUMOR BLOOD FLOW; VASCULAR DISEASE; VOMITING;

ANIMALS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; NEOPLASMS; POLYETHYLENE GLYCOLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77649176523     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2804     Document Type: Article

References (50)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-70.
2. Robaye B, Mosselmans R, Fiers W, Dumont JE, Galand P. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Pathol 1991;138:447-53.
3. Nobuhara M, Kanamori T, Ashida Y, et al. The inhibition of neoplastic cell proliferation with human natural tumor necrosis factor. Jpn J Cancer Res 1987;78:193-201.
4. Aoki M, Kuwamura M, Kotani T, et al. In vitro cytotoxicity of recombinant human-TNF-α and actinomycin D on canine normal and tumor cells. J Vet Med Sci 1998;60:1087-91.
5. Aoki M, Sasaki N, Nomura K, et al. Cytotoxicity induced by recombinant human tumor necrosis factor-α dependent on the types of its receptors on canine cells. J Vet Med Sci 1998;60:889-95.
6. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E III, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988;6:344-50.
7. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988;80: 1039-44.
8. Creaven PJ, Plager JE, Dupere S, et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987;20:137-44.
9. Lejeune FJ, Kroon BB, Di Filippo F, et al. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001;10:821-32, ix.
10. Eggermont AM, Ten Hagen TL. Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Curr Oncol Rep 2003;5:79-80.
11. van Etten B, van Geel AN, de Wilt JH, Eggermont AM. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003;10:32-7.
12. Lans TE, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Sewart-Treves lymphangiosarcoma. Ann Surg Oncol 2002;9:1004-9.
13. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BB. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002;9:968-74.
14. Fraker DL, Pass HJ. Biologic therapy with TNF: Systemic administration and isolated limb perfusion. In: DeVita VT, Hellman S, Rosenberg SA, editors. Biol Ther Cancer. Philadelphia: Lippincott; 1995, p. 329-45.
15. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-21.
16. Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA. Poly (ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 2002;80:259-71.
17. Tsutsumi Y, Kihira T, Tsunoda S, et al. Molecular design of hybrid tumor necrosis factor-α III: Polyethylene glycol-modified tumor necrosis factor-α has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation. J Pharmacol Exp Ther 1996;278:1006-11.
18. Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. Polyethylene glycoldiacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm Res 2002;19:1424-9.
19. Savva M, Duda E, Huang L. A genetically modified recombinant tumor necrosis factor-α conjugated to the distal terminals of liposomal surface grafted polyethyleneglycol chains. Int J Pharm 1999; 184:45-51.
20. Li YP, Pei YY, Ding J, et al. PEGylated recombinant human tumor necrosis factor α: preparation and anti-tumor potency. Acta Pharmacol Sin 2001;22:549-55.
21. Tsutsumi Y, Kihira T, Yamamoto S, et al. Chemical modification of natural human tumor necrosis factor-α with polyethylene glycol increases its anti-tumor potency. Jpn J Cancer Res 1994;85:9-12.
22. Tsutsumi Y, Kihira T, Tsunoda S, et al. Intravenous administration of polyethylene glycol-modified tumor necrosis factor-α completely regressed solid tumor in Meth-A murine sarcoma model. Jpn J Cancer Res 1994;85:1185-8.
23. Tsunoda S, Ishikawa T, Yamamoto Y, et al. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-α: a novel polymer-conjugation technique with a reversible amino-protective reagent. J Pharmacol Exp Ther 1999;290:368-72.
24. Walley KR, Hebert PC, Wakai Y, Wilcox PG, Road JD, Cooper DJ. Decrease in left ventricular contractility after tumor necrosis factor-α infusion in dogs. J Appl Physiol 1994;76:1060-7.
25. Eichenholz PW, Eichacker PQ, Hoffman WD, et al. Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. Am J Physiol 1992;263:H668-75.
26. Natanson C, Eichenholz PW, Danner RL, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989;169:823-32.
27. Mitaka C, Hirata Y, Ichikawa K, et al. Effects of TNF-α on hemodynamic changes and circulating endothelium-derived vasoactive factors in dogs. Am J Physiol 1994;267:H1530-6.
28. Smith CW, Entman ML, Lane CL, et al. Adherence of neutrophils to canine cardiac myocytes in vitro is dependent on intercellular adhesion molecule-1. J Clin Invest 1991;88:1216-23.
29. Dore M, Sirois J. Regulation of P-selectin expression by inflammatory mediators in canine jugular endothelial cells. Vet Pathol 1996;33:662-71.
30. Tremblay C, Paradis M, Dore M. Expression of E- and P-selectin in tumor necrosis factor-induced dermatitis in dogs. Vet Pathol 2001; 38:261-8.
31. Schroth MK, Shasby DM. Cytokine-mediated changes in PMN adherence to canine tracheal epithelial cells. Chest 1992;101:39-40S.
32. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-56.
33. Vail DM, Thamm DH. Spontaneously occurring tumors in companion animals as models for drug development. In: Teicher BA, Andrews PA, editors. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. 2nd ed. Totowa (NJ): Humana Press; 2004, p. 259-84.
34. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984;312:724-9.
35. Tsutsumi Y, Tsunoda S, Kamada H, et al. Molecular design of hybrid tumour necrosis factor-α. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-α affects its anti-tumour potency. Br J Cancer 1996;74:1090-5.
36. Vail DM. Veterinary Co-operative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Compar Oncol 2004;2:194-213.
37. Wagner JG. Non-compartmental and system analysis. In: Wagner JG, editor. Pharmacokinetics for the Pharmaceutical Scientist. Lancaster (PA): Technomic Publishing; 1993, p. 83-102.
38. Anderson H, Price P, Blomley M, Leach MO, Workman P. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer 2001;85:1085-93.
39. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005;97:172-87.
40. DeStefani A, Valente G, Forni G, Lerda W, Ragona R, Cortesina G. Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations. J Immunother 1996;19:125-33.
41. Lassen ED. Laboratory detection of muscle injury. In: Thrall MA, editor. Veterinary Hematology and Clinical Chemistry. Philadelphia: Lippincott Williams & Wilkins; 2004, p. 417-20.
42. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987;47:2986-9.
43. Selby P, Hobbs S, Viner C, et al. Tumour necrosis factor in man: clinical and biological observations. Br J Cancer 1987;56:803-8.
44. Taguchi T. Phase I study of recombinant human tumor necrosis factor (rHu-TNF: PT-050). Cancer Detect Prev 1988;12:561-72.
45. Esmon CT. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract Res Clin Haematol 1999;12:343-59.
46. Evans DA, Jacobs DO, Wilmore DW. Tumor necrosis factor enhances glucose uptake by peripheral tissues. Am J Physiol 1989; 257:R1182-9.
47. Tredget EE, Yu YM, Zhong S, et al. Role of interleukin 1 and tumor necrosis factor on energy metabolism in rabbits. Am J Physiol 1988; 255:E760-8.
48. Bertilaccio MT, Grioni M, Sutherland BW, et al. Vasculature-targeted tumor necrosis factor-α increases the therapeutic index of doxorubicin against prostate cancer. Prostate 2008;68:1105-15.
49. Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-α. Clin Cancer Res 2006;12:175-82.
50. Seynhaeve AL, Hoving S, Schipper D, et al. Tumor necrosis factor α mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007;67: 9455-62.